METHODS:
We retrospectively evaluated data of 3 patients that received AAT as second-line therapy for acute SR-GvHD. Patients had undergone allogeneic HSCT from related or unrelated donors with reduced-intensity conditioning regimens (RIC) and had developed acute GvHD unresponsive to high dose steroids. Steroid refractoriness is defined as progression in GvHD within 3–5 days of starting the treatment or an incomplete response by 7–14 days. All patients’ GvHD status was classified by Glucksberg criteria.11 Endoscopic and colonoscopic examinations were performed and intestinal GvHD was proven by biopsies for all patients. All patients had received multiple second-line therapies before AAT administration.